EPISODE · Mar 10, 2026 · 7 MIN
Barclays Miami: Latigo Bio aims to have a best-in-class Nav1.8 - a new class of medicines for pain that is the biotech sector's answer to the challenges that are presented by opioids
from BiotechTV - News · host BiotechTV
CEO Nima Farzan explains the science behind Nav1.8, why he believes Latigo's asset could be best in class, and the status of the company's development program.
Embed this episode
Ready to play
Barclays Miami: Latigo Bio aims to have a best-in-class Nav1.8 - a new class of medicines for pain that is the biotech sector's answer to the challenges that are presented by opioids
0:00
7:34
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 7 minutes long.
When was this BiotechTV - News episode published?
This episode was published on March 10, 2026.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!